These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27826183)

  • 21. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
    Kumagai Y; Hasunuma T; Sakai S; Ochiai H; Samukawa Y
    PLoS One; 2015; 10(10):e0139873. PubMed ID: 26444986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
    Gottfridsson C; Carlson G; Lappalainen J; Sostek M
    Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
    Das S; Armstrong J; Mathews D; Li J; Edeki T
    J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intravenous zanamivir on cardiac repolarization.
    Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
    Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
    Kim S; Lee H; Ko JW; Kim JR
    Clin Ther; 2019 Nov; 41(11):2204-2218. PubMed ID: 31564512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A thorough QT study of guanfacine.
    Martin P; Satin L; Kahn RS; Robinson A; Corcoran M; Purkayastha J; Youcha S; Ermer JC
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):301-16. PubMed ID: 25109412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study.
    Carlson GF; Tou CK; Parikh S; Birmingham BK; Butler K
    Diabetes Ther; 2011 Sep; 2(3):123-32. PubMed ID: 22127822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
    March B; Cardi T
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
    Taubel J; Naseem A; Harada T; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):391-400. PubMed ID: 20406223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
    Green CL; Whellan DJ; Lambe L; Bellibas SE; Wijngaard P; Prats J; Krucoff MW
    J Cardiovasc Pharmacol; 2013 Nov; 62(5):466-78. PubMed ID: 23921301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.
    Pinto R; l'Hostis P; Patat A; Homery MC; Falcão A; Nunes T; Rocha JF; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):454-62. PubMed ID: 27137718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
    German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
    Donado E; Izquierdo I; Pérez I; García O; Antonijoan RM; Gich I; Solans A; Peña J; Morganroth J; Barbanoj MJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):401-10. PubMed ID: 20406224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study.
    Rosignoli MT; Di Loreto G; Dionisio P
    Clin Drug Investig; 2010; 30(1):5-14. PubMed ID: 19995094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
    McCrea J; Mostoller K; Mahon C; Liu C; Liu F; Zajic S; Panebianco D; Chakravarthy M; Brandquist C; Gutierrez M; Stoch SA
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):861-870. PubMed ID: 31175709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.